|
|
 | | | |
- close
- close
- close
- close
Sanofi-Aventis SA (SNY) |
Market Intelligence Center
Jun 17
Comment
Sanofi-Aventis (NYSE: SNY) closed Friday's trading session at $53.74. In the past year, the stock has hit a 52-week low of $35.22 and 52-week high of $55.94. Sanofi (SNY) stock has been showing support around $53.14 and resistance in the $54.40...
FiercePharma
Jun 13
Comment
On Tuesday, the SEC filed civil complaints against two brothers accused of buying stock based on secret knowledge of the then-upcoming takeover--the 8th case the Commission has brought against insider trading connected to that deal, it says.
Cloud Computing
Jun 12
Comment
PARIS
and
SAN DIEGO
,
June 12, 2013
/PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that it has honored Sanofi-Aventis Recherche & Developpement...
FiercePharma
Jun 12
Comment
The FDA two days ago gave its approval to Sanofi's Fluzone Quadrivalent, a 4-1 influenza vaccine, and now the estimates on the revenue upside are starting to roll in. GlobalData says they look very promising.
Market Intelligence Center
Jun 11
Comment
Sanofi-Aventis (NYSE: SNY) closed Monday's trading session at $53.29. In the past year, the stock has hit a 52-week low of $34.16 and 52-week high of $55.94. Sanofi (SNY) stock has been showing support around $52.93 and resistance in the $53.77...
FierceBiotech
Jun 10
Comment
Lemtrada, Sanofi's "new" drug for multiple sclerosis, helps demonstrate just how plagued the drug-development process can be, with a series of false starts and sudden stops as it was handed off from one company to the next. Today, Reuters' Ben...
FiercePharma
Jun 10
Comment
The 2013-2014 influenza season will be the first in which vaccines will contain two A and two B strains, and Sanofi-Pasteur says it will be part of the change to the expanded program. The FDA has approved its 4-in-1 influenza vaccine in the U.S.,...
Benzinga
Jun 7
Comment
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.
In the report, Jefferies noted, “We reiterate Novartis as our Top European and...
FiercePharma
Jun 7
Comment
With competition fierce in the diabetes category, Sanofi is pushing its franchise in multiple directions, issuing new devices, new drugs and new markets to secure its position.
FierceBiotech
Jun 7
Comment
As a major medical meeting brings the spotlight to new diabetes drugs this month, Sanofi has begun reaching out to the media to secure center-stage status for data on its new therapies. The French drug giant has a next-generation version of its...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
